Endo International (ENDP) is a specialty healthcare company focused on branded and generic pharmaceuticals and devices. The Dublin, Ireland-based leading global healthcare company has several products including Lidoderm, Opana ER, Voltaren Gel, Frova, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Both Endo’s Branded Pharmaceuticals and Generic Pharmaceuticals division has been performing well.
Endo has implemented a growth-by-acquisition strategy. Endo has entered into an agreement to acquire privately held Par Pharmaceutical in the third quarter of 2015. The acquisition of Par Pharma will boost Endo’s generics portfolio and pipeline. The deal is expected to be earnings accretive in the first year of completion and result in double-digit accretion in 2016.
Endo’s track record has been pretty impressive with the company beating estimates in three of the last four quarters with an average earnings surprise of 6.58%.
Currently, Endo has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo beat on earnings by 6 cents. Our consensus called for EPS of $1.02, and the company reported EPS of $1.08.
Revenue: Revenues were slightly above expectations. Endo posted revenues of $735.2 million, compared to our consensus estimate of $731 million.
Key Stats: In the second quarter of 2015, U.S. Branded Pharmaceuticals business benefited from inclusion of Auxilium Pharmaceuticals revenues. The company reiterated its 2015 guidance. The company expects earnings per share for 2015 in the range of $4.40 to $4.60. The company expects revenues in the range of $2.90 billion to $3.00 billion.
Check back later for our full write up on this Endo earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment